Uptravi vs. Letairis

Uptravi (selexipag) and Letairis (ambrisentan) are used to treat pulmonary arterial hypertension.

Uptravi and Letairis belong to different drug classes. Uptravi is a prostacyclin receptor agonist and Letairis is an endothelin receptor antagonist.

Side effects of Uptravi and Letairis that are similar include headache, vomiting, and flushing (warmth, redness, or tingly feeling).

Side effects of Uptravi that are different from Letairis include diarrhea, jaw pain, nausea, muscle pain, pain in extremities, joint pain, low levels of iron in the blood (anemia), decreased appetite, and rash.

Side effects of Letairis that are different from Uptravi include stuffy nose, runny nose, sinus pain, abdominal or stomach pain, constipation, and sore throat.

Both Uptravi and Letairis may interact with rifampin.

Uptravi may also interact with gemfibrozil, teriflunomide, and deferasirox.

Letairis may also interact with cyclosporine, omeprazole, antibiotics, and HIV medicines.

Common side effects of Uptravi include:

Side effects of Uptravi include:

• headache,
• diarrhea,
• jaw pain,
• nausea,
• muscle pain,
• vomiting,
• pain in extremities,
• flushing (warmth, redness, or tingly feeling),
• joint pain,
• low levels of iron in the blood (anemia),
• decreased appetite, or
• rash

Common side effects of Letairis include:

• stuffy nose,
• runny nose,
• sinus pain,
• headache,
• abdominal or stomach pain,
• vomiting,
• constipation,
• sore throat, or
• flushing (warmth, redness, or tingly feeling under your skin).

Tell your doctor if you have unlikely but serious side effects of Letairis including:

• fast heartbeat,
• extreme tiredness,
• swelling ankles or feet,
• sudden or unexplained weight gain, or
• trouble breathing.

Uptravi (selexipag) is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Letairis (ambrisentan) is an endothelin receptor antagonist used to treat pulmonary arterial hypertension (PAH). Letairis blocks the effects of endothelin-1, helping to decrease the blood pressure in the lungs, slow the worsening of symptoms, and improve your ability to exercise.

Uptravi may interact with strong inhibitors of CYP2C8 (e.g., gemfibrozil). Tell your doctor all medications and supplements you use.

Letairis may interact with cyclosporine, omeprazole, rifampin, antibiotics, or HIV medicines. Tell your doctor all medications you use.

The starting dose of Uptravi is 200 mcg twice daily. Increase the dose of Uptravi by 200 mcg twice daily at weekly intervals to the highest tolerated dose up to 1600 mcg twice daily.

The adult starting dose of Letairis is 5 mg once daily, and may be increased to 10 mg once daily if 5 mg is tolerated.